0.24
0.24 (0%)
As of Dec 15, 2023
Impel Pharmaceuticals Inc [IMPL]
Source:
Company Overview
We are a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the Central Nervous System, or CNS. Our company was founded on the premise that the upper nasal space can be an optimal treatment entry point for CNS and other diseases where rapid vascular absorption can result in superior clinical outcomes.
| Country | United States |
| Headquarters | seattle, washington |
| Phone Number | 206-568-1466 |
| Industry | manufacturing |
| CEO | Adrian Adams |
| Website |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $5 |
| Operating Profit | $-12.8 |
| Net Income | $-13.8 |
| Net Cash | $-55.9 |
Profit Ratios
| Gross Margin | $2.8 |
| Operating Margin | -255 |
| Profit as % of Revenues | 55.6% |
| Profit as % of Assets | -22.3% |
| Profit as % of Stockholder Equity | 15% |
Management Effectiveness
| Return on Equity | 15% |
| Return on Assets | -39.4% |
| Turnover Ratio | 0.1% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $35.1 |
| Total Liabilities | $127 |
| Operating Cash Flow | $-61.1 |
| Investing Cash Flow | $-1.9 |
| Financing Cash Flow | $7.1 |
